Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients.
Vlachová M, Pečinka L, Gregorová J, Moráň L, Růžičková T, Kovačovicová P, Almáši M, Pour L, Štork M, Hájek R, Jelínek T, Popková T, Večeřa M, Havel J, Vaňhara P, Ševčíková S. Vlachová M, et al. Among authors: jelinek t. Sci Rep. 2024 Aug 13;14(1):18777. doi: 10.1038/s41598-024-69408-1. Sci Rep. 2024. PMID: 39138296 Free PMC article.
Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data.
Maisnar V, Pour L, Spicka I, Jelinek T, Minarik J, Jungova A, Stork M, Straub J, Radocha J, Pika T, Pospisilova L, Nair S, Kunovszki P, Hajek R. Maisnar V, et al. Among authors: jelinek t. Clin Lymphoma Myeloma Leuk. 2023 Feb;23(2):145-153. doi: 10.1016/j.clml.2022.11.001. Epub 2022 Nov 6. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36567210
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data.
Sandecka V, Pour L, Špička I, Minařík J, Radocha J, Jelínek T, Pavlíček P, Jungová A, Kessler P, Wróbel M, Štork M, Štraub J, Pika T, Čápková L, Ševčíková S, Maisnar V, Hájek R. Sandecka V, et al. Among authors: jelinek t. Neoplasma. 2022 Dec;69(6):1474-1479. doi: 10.4149/neo_2022_220813N827. Neoplasma. 2022. PMID: 36591805
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.
Stork M, Spicka I, Radocha J, Minarik J, Jelinek T, Jungova A, Pavlicek P, Pospisilova L, Sedlak F, Straub J, Pika T, Knechtova Z, Fidrichova A, Boichuk I, Sevcikova S, Maisnar V, Hajek R, Pour L. Stork M, et al. Among authors: jelinek t. Ann Hematol. 2023 Jun;102(6):1501-1511. doi: 10.1007/s00277-023-05188-4. Epub 2023 Apr 24. Ann Hematol. 2023. PMID: 37088816 Free PMC article.
Immunoablative therapy followed by autologous hematopoietic stem cell transplantation as the first-line disease-modifying therapy in patients with multiple sclerosis.
Lachnit M, Revendova KZ, Hradilek P, Bunganic R, Koristek Z, Jelinek T, Skutova M, Piza R, Volny O, Hajek R, Bar M. Lachnit M, et al. Among authors: jelinek t. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024 Mar;168(1):50-54. doi: 10.5507/bp.2023.023. Epub 2023 Jun 16. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2024. PMID: 37337857 Free article.
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Kapoor P, Nathwani N, Jelinek T, Pour L, Perrot A, Dimopoulos MA, Huang SY, Spicka I, Chhabra S, Lichtman E, Mateos MV, Kanagavel D, Zhao L, Guillemin-Paveau H, Macé S, van de Velde H, Richardson PG. Kapoor P, et al. Among authors: jelinek t. Eur J Haematol. 2024 Nov;113(5):593-605. doi: 10.1111/ejh.14270. Epub 2024 Jul 12. Eur J Haematol. 2024. PMID: 38993150 Clinical Trial.
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry.
Muronova L, Soucek O, Zihala D, Sevcikova T, Popkova T, Plonkova H, Venglar O, Pour L, Stork M, Rihova L, Bezdekova R, Minarik J, Látal V, Novak M, Jungova A, Dekojova T, Straub J, Spacek M, Rezacova V, Maisnar V, Radocha J, Hajek R, Jelinek T. Muronova L, et al. Among authors: jelinek t. Eur J Haematol. 2025 Jan;114(1):155-163. doi: 10.1111/ejh.14316. Epub 2024 Oct 10. Eur J Haematol. 2025. PMID: 39390851 Free PMC article.
One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic.
Šušol O, Šušolová B, Klempíř O, Navrátil M, Gumulec J, Kořístek Z, Ďuraš J, Kaščák M, Mihályová J, Stejskal L, Jelínek T, Richterová P, Szeligová L, Plonková H, Zuchnická J, Dluhošová B, Demel I, Buffa D, Hradská K, Popková T, Muroňová L, Lachnit M, Lančová K, Hájek R. Šušol O, et al. Among authors: jelinek t. Cancer Med. 2024 Dec;13(24):e70503. doi: 10.1002/cam4.70503. Cancer Med. 2024. PMID: 39711119 Free PMC article.
303 results